Israeli Biomed Firm Silenseed Raises $10M

August 1, 2017 | Silenseed, an Israeli, clinical-stage bio-pharmaceutical company that develops cancer therapies, is raising $10 million. Founded in 1999 by Amotz Shemi, the company is planning to use the money to fund the second phase of a trial, which was recently approved by the FDA, to develop a pancreatic cancer treatment. Silenseed uses a targeted RNA interference (RNAi) to develop the cancer drugs and delivery systems for treatment.